HTG Molecular Diagnostics, Inc. (HTGM)
(Delayed Data from NSDQ)
$2.59 USD
+0.10 (4.02%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.58 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.59 USD
+0.10 (4.02%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.58 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of -25% and 1%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 4.88% and 8.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
TransMedics (TMDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of 68% and 19.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Molecular Templates Inc. (MTEM) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -56% and 63.99%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
HTG Molecular Diagnostics, Inc. (HTGM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of 21.15% and 44.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 36.36% and 11.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ReWalk Robotics (RWLK) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
ReWalk (RWLK) delivered earnings and revenue surprises of -50% and 51.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
HTG Molecular Diagnostics, Inc. (HTGM) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
HTG Molecular Diagnostics, Inc. (HTGM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of -9.52% and 4.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 95% and 2.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
HTG Molecular Diagnostics, Inc. (HTGM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of -14.08% and 15.43%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ConforMIS (CFMS) delivered earnings and revenue surprises of -28.57% and 11.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: HTG Molecular Diagnostics, Inc. (HTGM) Q4 Earnings Expected to Decline
by Zacks Equity Research
HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HTG Molecular Diagnostics, Inc. (HTGM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of 0.00% and 3.32%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will HTG Molecular Diagnostics, Inc. (HTGM) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for May 14th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 14th
HTG Molecular Diagnostics Inc (HTGM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
HTG Molecular Diagnostics Inc (HTGM) delivered earnings and revenue surprises of 0.00% and -2.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
HTG Molecular Diagnostics Inc (HTGM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
HTG Molecular Diagnostics Inc (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: HTG Molecular Diagnostics, Inc. (HTGM) Q4 Earnings Expected to Decline
by Zacks Equity Research
HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: HTG Molecular Diagnostics, Inc. (HTGM) Q4 Earnings Expected to Decline
by Zacks Equity Research
HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HTG Molecular Diagnostics, Inc. (HTGM) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of -7.14% and -3.91%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
HTG Molecular Diagnostics, Inc. (HTGM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HTG Molecular Diagnostics, Inc. (HTGM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of -13.33% and 4.62%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate HTG Molecular Diagnostics, Inc. (HTGM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HTG Molecular Diagnostics, Inc. (HTGM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of -11.76% and 15.84%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?